Author/Authors :
Rezaei, Negar Non-Communicable Diseases Research Center - Endocrinology and Metabolism Population Sciences Institute - Tehran University of Medical Sciences, Tehran, Iran , Maghsodlu, Mahtab Blood Transfusion Research Centre - High Institute for Research and Education in Transfusion Medicine, Tehran, Iran , Sheidaei, Ali Department of Epidemiology and Biostatistics, School of Public Health - Tehran University of Medical Sciences, Tehran, Iran , Amini Kafiabad, Sedigheh Department of Epidemiology and Biostatistics - School of Public Health - Tehran University of Medical Sciences, Tehran, Iran , Gohari, Kimiya Department of Biostatistics - Faculty of Medical Sciences - Tarbiat Modares University, Tehran, Iran , Zadsar, Maryam Department of Epidemiology and Biostatistics - School of Public Health - Tehran University of Medical Sciences, Tehran, Iran , Delavari, Farnaz Non-Communicable Diseases Research Center - Endocrinology and Metabolism Population Sciences Institute - Tehran University of Medical Sciences, Tehran, Iran , Sharifi, Zohreh Department of Epidemiology and Biostatistics - School of Public Health - Tehran University of Medical Sciences, Tehran, Iran , Yoosefi, Moein Department of Epidemiology and Biostatistics - School of Public Health - Tehran University of Medical Sciences, Tehran, Iran , Farzadfar, Farshad Department of Epidemiology and Biostatistics - School of Public Health - Tehran University of Medical Sciences, Tehran, Iran , Asadi-Lari,Mohsen Oncopathology Research Centre - Iran University of Medical Sciences, Tehran, Iran
Abstract :
High risk blood transfusions can cause a lot of financial and psychological burden to the com-munity. The prevalence of Hepatitis B is useful for evaluating the blood products' safety and donor selection methods. We aimed to predict the prevalence of hepatitis B in Iranian blood donors from 2000-2016. Methods: Positive cases of hepatitis B from 2006 to 2014 were collected from Iranian Blood Transfusion Or-ganization. This database was classified according to the age, provinces, and type of donation. Data was not existed in all subnational levels and all years, therefore, for predicting the hepatitis B prevalence, two separate, Spatio-temporal and mixed model (GLMM) were developed. Results: At the national level, the hepatitis B prevalence declined from 0.69 (0.51 to 0.90) in 2000 to 0.27 (0.21 to 0.33) in 2016. In first-time, regular, and repeated donors, this prevalence declined from 2.31 (1.74 to 2.31), 0.26 (0.19 to 0.34), and 0.51 (0.38 to 0.68) in 2000 to 0.87 (0.69 to 1.09), 0.09 (0.07 to 0.12), and 0.19 (0.14 to 0.24) in 2016. At the provincial level, the highest and lowest prevalence in 2016 was observed in North Khora-san and Gilan. With increasing age, the average prevalence of hepatitis B, increased. Conclusion: Prevalence of hepatitis B in Iranian blood donors has been reduced significantly over 17 years, but still new cases of hepatitis B are reported. By precise monitoring the donor selection process and implementing more sensitive laboratory screening, we can reduce the risk of new infectious agents.
